Northwest Biotherapeutics, Inc. filed its 10-K on Feb 28, 2023 for the period ending Dec 31, 2022. In this report its auditor, Cherry Bekaert LLP - Cherry, Bekaert & Holland, LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.455 USD | -0.30% | -5.21% | -35.09% |
05-10 | Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03-21 | Northwest Biotherapeutics, Inc. Appoints Pat Sarma to Its Board of Directors | CI |
1st Jan change | Capi. | |
---|---|---|
-35.09% | 553M | |
+11.16% | 115B | |
+12.85% | 106B | |
-4.32% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-11.74% | 17.56B | |
-40.50% | 17.32B | |
+7.61% | 14.03B | |
+32.88% | 12.13B |
- Stock Market
- Equities
- NWBO Stock
- News Northwest Biotherapeutics, Inc.
- Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt